Skip to content
OpenCapital
Get started

ClearPoint Neuro CLPT Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

IAR
Integra LifeSciencesIART
——
Merit Medical Systems logo
Merit Medical SystemsMMSI
——
ITG
Integer HoldingsITGR
——
Ginkgo Bioworks logo
Ginkgo BioworksDNA
——

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's deferred revenue, net of current portion?
ClearPoint Neuro (CLPT) reported deferred revenue, net of current portion of $608K in Q1 2026.
How has ClearPoint Neuro's deferred revenue, net of current portion changed year-over-year?
ClearPoint Neuro's deferred revenue, net of current portion increased by 70.3% year-over-year, from $357K to $608K.